NEW YORK (GenomeWeb) – Qiagen said yesterday that it has inked a master collaboration for companion diagnostics codevelopment with Array BioPharma, the 15th pharma agreement of this type.
The way Health and Human Services Chief Technology Officer Susannah Fox sees it, the U.S. government totally missed the Internet boom and has been trying to catch up with ever since.
“I would say gently that the government was caught flat footed when the Internet came about,” she said
Advanced Accelerator Applications S.A. (NASDAQ: AAAP) announced an exclusive license agreement with Johns Hopkins University in Baltimore, Maryland to develop and market PSMA-SR6, a receptor ligand of Prostate-Specific Membrane Antigen (PSMA) for clinical therapeutic and diagnostic purposes. AAA will focus on developing this treatment and its companion diagnostic for prostate cancer through novel molecular nuclear medicine techniques similar to those implemented for the development of Lutathera and Somakit. Prostate cancer affects nearly 1 in 7 men during their lifetime worldwide.
AstraZeneca, along with its global biologics research and development arm, MedImmune, and Moderna Therapeutics today announced a new collaboration to discover, co-develop and co-commercialize messenger RNA (mRNA) therapeutic candidates for the treatment of a range of cancers. The collaboration is in addition to the agreement announced by the companies in 2013 to develop mRNA Therapeutics™ for the treatment of cardiovascular, metabolic and renal diseases as well as selected targets in oncology.
Leading global start up accelerator Dreamit today announced that it has renewed its partnerships with industry leaders Independence Blue Cross (Independence) and Penn Medicine to advance entrepreneurship and innovation in health care. The continued support follows significant upgrades to the Dreamit Health program announced earlier this year. The new model includes key changes designed to appeal to a broader range of entrepreneurs, including a no-cash/no-equity offer to draw later-stage companies and serial entrepreneurs who would not typically consider an accelerator program.
Biological researchers should be able to share datasets the same way they share published scientific articles — at least, that’s what the National Institutes of Health is trying to ensure with a new project.
NIH is building a virtual space called “the Commons,” where researchers can one day do just that: share data, software and any other virtual tools or research processes in a way that’s “Findable, Accessible, Interoperable and Reusable,” or “FAIR.”
Rewards for creative people; investments in new ideas that challenge the power of the Pope and sovereign rulers, that give impetus to science and give birth to the new class of merchant nobles creators of wealth with their businesses: this the Renaissance.
The American Medical Association has invested $15 million to become founding partner of Health2047, a high-tech incubator that will explore innovative solutions to some of the biggest challenges facing the nation’s 1.1 million physicians and their patients.
Sucampo Pharmaceuticals (NASDAQ:SCMP) has acquired an option to commercialize a drug candidate aimed at preventing colon cancer among a high-risk group of patients in a deal worth up to $190 million. Sucampo unveiled Monday its agreement with Tuscon, Arizona-based Cancer Prevention Pharmaceuticals Inc. for the option to acquire an exclusive license to commercialize for a drug candidate in Phase III clinical trials. The therapy is aimed at treating a genetic condition called Familial Adenomatous Polyposis, or FAP, which can develop into colon cancer if it’s left untreated.
Thursday January 21, 2016 from 5:00 PM to 7:00 PM EST
Johns Hopkins Montgomery County Campus is also a site for the popular Osher Lifelong Learning Institute. Geared toward retirees, these non-credit classes cover topics including opera, literature, history, politics and more.
The campus is home to approximately 35 research companies and entrepreneurs. Scientists on campus are studying cervical cancer, Alzheimer’s disease, cell therapy, proteins and other health issues. Other companies focus on technology, medical devices and consulting services. The Rockville Science Center’s administrative offices are located here. Start-up companies, second-stage businesses and more established companies are welcome.